Corporate Updates - Quantum BioPharma Ltd. is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [1][5] - The company has drug candidates at various stages of development, with a lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation associated with multiple sclerosis [5] Debt Settlement - On August 12, 2025, the company settled outstanding debt of $26,812.50 USD with a creditor by converting it into 1,102 Class B Shares at a price of $24.33 USD per share [2] Grant of Restricted Stock Units - On August 15, 2025, the company granted 800 restricted stock units (RSUs) each to two Clinical Advisors, Peter Stys and Jack Antel, with specific vesting conditions tied to regulatory filings [3][8] - The RSUs and Creditor Shares are subject to a statutory hold period of four months and one day [3] Advisory Board Changes - The company terminated the Board Advisor Agreement with Kevin Malone effective August 15, 2025, resulting in his departure from the advisory role [4] Strategic Investments - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the OTC version of its product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty will decrease to 3% [5] - The company also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [5]
Quantum BioPharma Announces Corporate Updates